Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
ABRAXANE® Extends Survival By Nearly Two Months For Patients With Advanced Pancreatic Cancer

MANHATTAN BEACH, Calif., Jan. 22, 2013 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce that today Celgene Corporation (Celgene) reported that the combination of its chemotherapeutic drug ABRAXANE® with gemcitabine improved overall survival in patients with metastatic pancreatic cancer by nearly two months (8.5 months vs. 6.7 months) when compared with gemcitabine alone. According to Celgene, this combination also demonstrated a 59 percent increase in one-year survival compared to patients receiving gemcitabine alone.

(Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO)

"The positive results of this trial indicate another step forward in the treatment of this insidious disease where historically few effective treatment options have existed.  This success also illustrates that clinical trials can give pancreatic cancer patients access to state-of-the art treatments that may be their best option.  We are pleased that patients will have another choice when making treatment decisions," stated Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network.  "Further, this positive news brings us one step closer to doubling the survival rate of pancreatic cancer by 2020."

The phase III study included 861 metastatic pancreatic cancer patients from around the world.  Celgene plans to submit their findings to the FDA for approval of ABRAXANE in pancreatic cancer.  ABRAXANE was previously approved for breast cancer in 2005 and in October 2012 was approved for a type of lung cancer. It is a form of the chemotherapy drug paclitaxel that is modified by the addition of a human protein called albumin.

The Pancreatic Cancer Action Network encourages all patients to consider clinical trials when exploring treatment options. The organization has a comprehensive up-to-date database of all approved pancreatic cancer-specific clinical trials taking place nationwide and can do a customized eligibility search for patients through our Patient and Liaison Services program.

For more information about the Pancreatic Cancer Action Network and clinical trials visit www.pancan.org.  

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

For information on the listed expert, click appropriate link.
Julie Fleshman
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=75525

SOURCE Pancreatic Cancer Action Network

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
This independent report from Info-Tech evaluates and scores 14 companies in the Virtual Machine Backup market. It can help you understand what's new in the virtual backup market, evaluate virtual backup vendors and products for your needs and determine which products are most app...
Avaya has escalated its efforts to get customers to fast-track to the cloud with the first of several sweeping initiatives that will optimize solutions and processes for delivery of collaboration as a service (CaaS) via the Avaya Collaborative Cloud. Strong demand for Avaya commu...
CodeFutures, a provider of agile Big Data technologies, on Tuesday announced the release of Cory Isaacson’s newest book, “Understanding Big Data Scalability.” Isaacson is the CEO/CTO for CodeFutures and an industry-leading innovator of data management software. “Understanding Big...
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a ...
Cloud Computing is evolving into a Big Three of Amazon Web Services, Google Cloud, and Microsoft Azure. Cloud 360: Multi-Cloud Bootcamp, being held Nov 4–5, 2014, in conjunction with 15th Cloud Expo in Santa Clara, CA, delivers a real-world demonstration of how to deploy and co...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

The SIGGRAPH 2014 Art Gallery will gather and present 14 outstanding, critical, and...